INOVIO Announces Pricing of Approximately $75 Million Public Offering
Inovio Pharmaceuticals priced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $75 million.
Stocks · News reference
FDA Approves First Plasmid DNA-based Immunotherapy For Adults With Recurrent Respiratory Papillomatosis
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — INOVIO PHARMACEUTICALS, INC. (INO)
Filed: 2026-11-05 AccNo: 0001193125-26-449853 Size: 141 KB Item 2.02: Results of Operations and Financial Condition
Inovio Schedules Third Quarter 2026 Financial Results Release
Inovio Pharmaceuticals will release its financial results for the third quarter of 2026 after market close on November 10, 2026.
HC Wainwright Upgrades Inovio Pharmaceuticals to Buy
HC Wainwright has upgraded Inovio Pharmaceuticals to a 'Buy' rating from 'Neutral', setting a price target of $5.
Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis
The U.S. Food and Drug Administration has granted accelerated approval to Inovio's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
Inovio Pharmaceuticals Secures $80.4 Million Judgment in Litigation Against VGXI and GeneOne
Inovio Pharmaceuticals, Inc. announced a favorable legal judgment totaling $80.4 million against VGXI, Inc. and GeneOne Life Science, though the company cautioned that collection remains uncertain.